139 related articles for article (PubMed ID: 9643530)
1. Impact of histology on the treatment outcome of metastatic or recurrent renal cell carcinoma.
Wu J; Caliendo G; Hu XP; Dutcher JP
Med Oncol; 1998 Apr; 15(1):44-9. PubMed ID: 9643530
[TBL] [Abstract][Full Text] [Related]
2. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
[TBL] [Abstract][Full Text] [Related]
3. Impact of histologic subtype and sarcomatoid transformation on metastasis in renal cell carcinoma: a single institute experience in 149 patients.
Tirumani SH; Souza D; Krajewski KM; Jagannathan JP; Ramaiya NH; Shinagare AB
Abdom Radiol (NY); 2016 Feb; 41(2):295-302. PubMed ID: 26867911
[TBL] [Abstract][Full Text] [Related]
4. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.
McGregor BA; McKay RR; Braun DA; Werner L; Gray K; Flaifel A; Signoretti S; Hirsch MS; Steinharter JA; Bakouny Z; Flippot R; Wei XX; Choudhury A; Kilbridge K; Freeman GJ; Van Allen EM; Harshman LC; McDermott DF; Vaishampayan U; Choueiri TK
J Clin Oncol; 2020 Jan; 38(1):63-70. PubMed ID: 31721643
[TBL] [Abstract][Full Text] [Related]
5. Comparable survival outcome between acquired cystic disease associated renal cell carcinoma and clear cell carcinoma in patients with end-stage renal disease: a multi-institutional central pathology study.
Kondo T; Sassa N; Yamada H; Takagi T; Iizuka J; Kobayashi H; Yoshida K; Fukuda H; Ishihara H; Tanabe K; Tsuzuki T
Pathology; 2021 Oct; 53(6):720-727. PubMed ID: 33947521
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
Mani S; Todd MB; Katz K; Poo WJ
J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
[TBL] [Abstract][Full Text] [Related]
7. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
8. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases.
de Peralta-Venturina M; Moch H; Amin M; Tamboli P; Hailemariam S; Mihatsch M; Javidan J; Stricker H; Ro JY; Amin MB
Am J Surg Pathol; 2001 Mar; 25(3):275-84. PubMed ID: 11224597
[TBL] [Abstract][Full Text] [Related]
9. Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease.
Molina AM; Tickoo SK; Ishill N; Trinos MJ; Schwartz LH; Patil S; Feldman DR; Reuter VE; Russo P; Motzer RJ
Am J Clin Oncol; 2011 Oct; 34(5):454-9. PubMed ID: 21127411
[TBL] [Abstract][Full Text] [Related]
10. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Moon KC; Ku JH
J Surg Oncol; 2007 Mar; 95(4):317-23. PubMed ID: 17066434
[TBL] [Abstract][Full Text] [Related]
11. High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features.
Achkar T; Arjunan A; Wang H; Saul M; Davar D; Appleman LJ; Friedland D; Parikh RA
PLoS One; 2017; 12(12):e0190084. PubMed ID: 29261796
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras.
Keskin SK; Msaouel P; Hess KR; Yu KJ; Matin SF; Sircar K; Tamboli P; Jonasch E; Wood CG; Karam JA; Tannir NM
J Urol; 2017 Sep; 198(3):530-537. PubMed ID: 28411072
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology.
Motzer RJ; Bacik J; Mariani T; Russo P; Mazumdar M; Reuter V
J Clin Oncol; 2002 May; 20(9):2376-81. PubMed ID: 11981011
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors.
Chahoud J; Msaouel P; Ross JA; McCormick BZ; Bathala TK; Gao J; Horn R; Xiao L; Sircar K; Campbell MT; Shah AY; Goswami S; Zurita AJ; Jonasch E; Matin SF; Wood CG; Karam JA; Sharma P; Tannir NM
Urol Oncol; 2021 Feb; 39(2):134.e9-134.e16. PubMed ID: 33187886
[TBL] [Abstract][Full Text] [Related]
16. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.
Nanus DM; Garino A; Milowsky MI; Larkin M; Dutcher JP
Cancer; 2004 Oct; 101(7):1545-51. PubMed ID: 15378501
[TBL] [Abstract][Full Text] [Related]
17. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
[TBL] [Abstract][Full Text] [Related]
18. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma.
Cheville JC; Lohse CM; Zincke H; Weaver AL; Blute ML
Am J Surg Pathol; 2003 May; 27(5):612-24. PubMed ID: 12717246
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy.
Dimarco DS; Lohse CM; Zincke H; Cheville JC; Blute ML
Urology; 2004 Sep; 64(3):462-7. PubMed ID: 15351571
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Patients With Advanced Renal Cell Carcinoma With Non-Clear Cell Histology Treated With Systemic Therapy.
Urman D; Deshler L; Weise N; Shabaik A; Derweesh I; Bagrodia A; Rose B; Herchenhorn D; McKay RR
Clin Genitourin Cancer; 2023 Dec; 21(6):660-668.e1. PubMed ID: 37858374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
